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Abstract  23 
Objective: To describe infants with acute gastroenteritis symptoms in primary and secondary 24 
care who have the Rotarix® vaccine-derived G1P[8] rotavirus strain identified in their stools.  25 
 26 
Design: Prospective national surveillance conducted by Public Health England (PHE). 27 
Rotavirus-positive samples from vaccine-eligible children are routinely submitted to PHE for 28 
confirmation and general practitioners are requested to complete a surveillance questionnaire 29 
for all cases. The modified Vesikari score was used to assess severity of gastroenteritis 30 
Setting: England, July 2013 to September 2016 31 
Results: 2,637 rotavirus strains were genotyped and 215 (8%) identified as the 32 
Rotarix®vaccine-derived G1P[8] strain. There were no Rotarix® vaccine-derived G1P[8] 33 
strains detected in unimmunised infants. Rotarix® vaccine-derived G1P[8] strains clustered 34 
around the time of rotavirus vaccination and were responsible for 82% (107/130) of 35 
rotavirus-positive samples in 2 month-olds and 68% (36/53) in 3 month-olds. However, 14 36 
samples were obtained more than 7 weeks after the last vaccination date; ten of these 37 
specimens were from six children who were subsequently diagnosed with severe combined 38 
immune deficiency (SCID). Diarrhoea was the single most common presenting symptom 39 
(83.0%) in infants with Rotarix® vaccine-derived G1P[8] strains, who were also less likely to 40 
present with fever, vomiting, dehydration or severe gastroenteritis.   41 
Conclusions 42 
Rotavirus identified in stools of infants around the time of their routine immunisations is 43 
most likely be the Rotarix® vaccine-derived G1P[8] strain. Infants with undiagnosed SCID at 44 
the time of rotavirus immunisation may experience prolonged gastroenteritis symptoms. The 45 
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majority of infants with vaccine strains in their stools more than 7 weeks after immunisation 46 
had SCID. 47 
  48 
4 
Introduction 49 
Rotavirus is the most common cause of diarrhoea leading to hospitalisation in young children 50 
and is associated with considerable healthcare utilisation (1-3). Prior to routine immunisation, 51 
rotavirus gastroenteritis (RVGE) was associated with more than 80,000 primary care 52 
consultations (2) and 13,000 hospitalisations in the UK each year among children under 5 53 
years (3). On 01 July 2013, a two-dose, oral live-attenuated monovalent rotavirus vaccine, 54 
Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium), was introduced into the UK 55 
national infant immunisation programme at 8 and 12 weeks of age. Despite strict age 56 
restrictions for administering both the first and the second dose of vaccine, the programme 57 
rapidly achieved a very high vaccine uptake of 93% for the two-dose schedule by 25 weeks 58 
of age and was associated with a subsequent 15% decrease in primary care attendance for 59 
childhood acute gastroenteritis (AGE) as well as a 77% reduction in laboratory-confirmed 60 
rotavirus infections and a 26% decline in all-cause AGE–associated hospitalisations across all 61 
age groups (4, 5).  62 
 63 
In England, hospital laboratories commonly employ a number of different rotavirus antigen 64 
tests with variable sensitivities and specificities to confirm the diagnosis of rotavirus 65 
gastroenteritis in children (6). A few of the larger specialist hospitals use more sensitive 66 
enzyme immunoassays and, less commonly, reverse-transcriptase polymerase chain reaction 67 
(RT-PCR) to confirm the diagnosis. Because of the variable testing practices, and as part of 68 
enhanced national surveillance to monitor the impact, effectiveness and safety of the infant 69 
rotavirus immunisation programme, Public Health England (PHE) requested hospital 70 
laboratories across England to submit all rotavirus-positive stool samples from children in the 71 
vaccine-eligible cohort to the national reference laboratory (Enteric Virus Unit; EVU) for 72 
confirmation and molecular characterisation. Surveillance of circulating rotavirus genotypes 73 
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before and since vaccine introduction has shown that the incidence of the previously most 74 
prevalent strain, G1P[8], on which the vaccine is based, has declined most significantly (7). 75 
At the same time, the genotype diversity of the remaining wild type rotavirus strains causing 76 
gastroenteritis has increased (7). Laboratory surveillance also identified a substantial 77 
proportion of samples as Rotarix®vaccine-derived-G1P[8] strains (7). Here we describe the 78 
characteristics of infants with confirmed Rotarix®vaccine-derived-G1P[8] strain identified in 79 
their stools following the introduction of the rotavirus vaccine into the national immunisation 80 
programme and discuss the implications of our findings for frontline clinicians assessing 81 
infants with acute gastroenteritis in primary and secondary care. 82 
 83 
Methods 84 
Hospital laboratories routinely report all clinically significant infections, including rotavirus, 85 
electronically to PHE through the second-generation surveillance system (SGSS). PHE 86 
conducts enhanced national surveillance of all reported rotavirus cases in the vaccine-eligible 87 
cohort in England. As part of enhanced surveillance, a questionnaire is sent to general 88 
practitioners (GPs) for each case, requesting the rotavirus immunisation history; between 01 89 
July 2013 and 30 June 2015, the questionnaire also requested information to complete a 90 
modified Vesikari score for cases (8, 9).  91 
 92 
Since the introduction of the rotavirus immunisation programme, all NHS laboratories have 93 
also been asked to routinely submit rotavirus-positive stool samples in vaccine-eligible 94 
children (i.e. those born since 01 May 2013) to the PHE EVU for confirmation (10-12) and 95 
molecular characterisation (13, 14). Samples from vaccine-eligible cases reported through 96 
SGSS and not submitted to PHE are actively followed-up with the reporting hospital virology 97 
department. Unlike hospital laboratories, methodologies used at PHE EVU determines wild-98 
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type rotavirus genotypes according to binomial classification using the virus VP4 (P) and 99 
VP7 (G) sequences (as GxP[x]) and further differentiates G1P[8] type viruses between wild-100 
type and vaccine-derived strains. Rotarix®vaccine-derived-G1P[8]  strains were defined 101 
either: (1) where the sequences of the VP4 and VP7 encoding genes (segments 4 and 9, 102 
respectively) demonstrated highest homology with Rotarix® sequences (accession numbers 103 
JX943612 and JX943614, respectively); and/or (2) through detection of the Rotarix® 104 
sequence using a previously published and validated qRT-PCR assay, specifically targeting 105 
the NSP2 gene (segment 8) of the Rotarix® strain (13).  106 
 107 
For this study, all cases identified with a Rotarix®vaccine-derived-G1P[8]  strain between 01 108 
July 2013 and 30 September 2016 were included in the analysis. For each case, the interval 109 
between the date of sample and the last dose of rotavirus vaccination was used to estimate the 110 
duration of shedding of the Rotarix®vaccine-derived-G1P[8]  strains. Infants with a shedding 111 
interval greater than seven weeks were considered as outliers based on the distribution of the 112 
data, and investigated further by requesting additional clinical details and underlying 113 
conditions from their GP and, if needed, hospital clinicians. Infants confirmed with 114 
Rotarix®vaccine-derived-G1P[8]  strains who were reported by their GP as unimmunised and 115 
those where the date of sample collection preceded the reported vaccination date were also 116 
followed-up to investigate the potential source of the Rotarix®vaccine-derived-G1P[8]  strain. 117 
 118 
Data Analysis 119 
Data are mainly descriptive. Non-normal data are presented as medians with interquartile 120 
ranges and compared using the Mann Whitney U test. Proportions are compared using the 121 
chi-squared or Fisher’s exact test, as appropriate. 122 
 123 
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Ethical Approval 124 
PHE has legal permission, provided by Regulation 3 of the Health Service (Control of Patient 125 
Information) Regulations 2002, to process confidential information for national surveillance 126 
of communicable diseases.    127 
(http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made).  This includes PHE's 128 
responsibility to monitor the safety and effectiveness of vaccines, and as such, individual 129 
patient consent is not required. 130 
 131 
Results 132 
During 01 July 2013 and 30 September 2016, 2,637 rotavirus strains were genotyped by PHE 133 
EVU and 215 (8%) identified as the Rotarix®vaccine-derived-G1P[8] strains. Of the 215 134 
strains, eight were from infants who were not UK residents and were, therefore, not followed-135 
up as part of national surveillance as they were not registered with a GP practice. 136 
Investigation of seven other cases initially reported as unimmunised by the GP confirmed that 137 
all had in fact received the rotavirus vaccine in the six weeks preceding the sample date. In 138 
five additional cases, the sample date was reported to be prior to the date of first vaccination, 139 
but subsequent investigation revealed that the vaccination date had been reported in error for 140 
three cases and the vaccine had in fact been given prior to the sample date. In the remaining 141 
two cases, the reported date of vaccination was for the second dose; both infants had been 142 
born prematurely and had received their first dose of rotavirus vaccine in hospital at an 143 
unspecified date, but prior to the sample date. There were, therefore, no Rotarix®vaccine-144 
derived-G1P[8]  strains isolated from unimmunised infants during the surveillance period, 145 
despite previous reports (7). 146 
 147 
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Rotarix®vaccine-derived-G1P[8] strains contributed 32% (12/37) of rotavirus-positive 148 
samples in infants aged  under 2 months (these infants were immunised at 6-8 weeks; i.e. 149 
before they become two months old), 82% (107/130) in 2 month-olds, 68% (36/53) in 3 150 
month-olds, 46% (11/24) in 4-month-olds, 19% (5/26) in 5 month-olds and less than 1% in 151 
older infants. There were 158 Rotarix®vaccine-derived-G1P[8] samples detected after a first 152 
dose of rotavirus vaccine and before the second dose, with a median of 12 (IQR7-21) days 153 
after vaccination (range, 0 days to 96 days). In addition, there were 49 samples with a 154 
Rotarix®vaccine-derived-G1P[8] strain detected after the second dose of rotavirus vaccine, 155 
with a median of 14 (IQR= 6-48) days after vaccination (range 2 to 420 days) (Figure 1). The 156 
interval between the sample date and vaccination was not significant between the first and 157 
second dose of Rotarix® (Mann-Whitney U test -8290, p=0.51). In the latter group, 19 158 
samples were identified with a Rotarix®vaccine-derived-G1P[8] strain more than seven 159 
weeks after the last rotavirus vaccination (Figure 1). Of these, six had an incorrect sample 160 
date recorded and were, therefore, re-classified. Ten of the remaining samples were from six 161 
children who were subsequently diagnosed with severe combined immune deficiency 162 
(SCID); three additional cases with sample dates of 112 days, 71 days and 57 days after 163 
vaccination, respectively, were from infants who did not have any reported underlying 164 
condition; one was subsequently diagnosed with intestinal obstruction.  165 
 166 
Based on the information in the clinical questionnaire completed by the GP, infants with a 167 
Rotarix®vaccine-derived-G1P[8] strain were younger than those with wild-type rotavirus 168 
gastroenteritis (Table 1). In the former group, diarrhoea was by far the most prevalent 169 
presenting symptom (83.0%) and 54.5% (68/127) presented with diarrhoea only. By 170 
comparison, although infants with wild-type rotavirus gastroenteritis (due to any circulating 171 
strain) nearly always also presented with diarrhoea (94.6%), other symptoms including fever 172 
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(48.4% vs. 20.2%, p<0.001) and vomiting (74.2% vs. 32.0%, p<0.001) were more prevalent 173 
when compared to infants with a Rotarix®vaccine-derived-G1P[8] strain. Notably, infants 174 
with wild-type rotavirus infection were less likely than those with a Rotarix®vaccine-derived-175 
G1P[8]  strain to present with diarrhoea only (without vomiting) (95/407 [23.3%] vs. 68/127 176 
[54.5%]; P<0.001). Infants with wild-type rotavirus gastroenteritis were also more likely to 177 
be dehydrated (25.1% vs. 11.4%, P=0.001) and have severe gastroenteritis according to the 178 
modified Verikari score (37.5% vs. 9.8%, P=0.001) compared to those with a 179 
Rotarix®vaccine-derived-G1P[8]  strain (Table 1).  180 
 181 
Discussion  182 
During the first three years of the infant rotavirus immunisation programme in England, one 183 
in twelve rotavirus strains detected in stool samples from infants in the vaccine-eligible 184 
cohort were Rotarix®vaccine-derived-G1P[8] strains. More than 93% of samples containing 185 
Rotarix®vaccine-derived-G1P[8] virus were found in infants within 7 weeks of their first or 186 
second Rotarix® vaccination at 8 and 12 weeks of age. Detection of Rotarix®vaccine-derived-187 
G1P[8]  strains in infants older than 5 months of age was associated with an underlying 188 
diagnosis of SCID; these infants continued to excrete the vaccine-derived for a long period. 189 
Infants with Rotarix®vaccine-derived-G1P[8]  strains presented predominantly with diarrhoea 190 
and, compared to those with wild-type rotavirus gastroenteritis, were less likely to be 191 
dehydrated or have severe gastroenteritis as assessed by the modified Vesikari score. 192 
 193 
Currently available point-of-care (POC) or rapid diagnostic tests for rotavirus do not 194 
differentiate between rotavirus strains as they are directed toward an antigen (VP6) common 195 
across all group A rotaviruses and/or utilise polyclonal reagents which do not discriminate 196 
between virus genotypes. Nucleic-Acid Amplification Test (NAAT)-based approaches are 197 
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capable of distinguishing genotypes, and – in the case of G1P[8] – wild from vaccine-derived 198 
strains. At present, commercial kit-based platforms do not offer this distinction as part of the 199 
multiplex designs, although laboratories may incorporate the test into any in-house 200 
methodologies after appropriate validation. The diagnostic tests commonly used by NHS 201 
hospital laboratories do not differentiate between wild-type and Rotarix®vaccine-derived-202 
G1P[8]  strains; this has important clinical implications. 203 
 204 
Vaccine-strains causing symptoms: clinical implications 205 
In our cohort, stool samples were submitted from symptomatic infants who were assessed in 206 
primary or secondary care because of parental concerns. In clinical trials, reported adverse 207 
events associated with Rotarix® vaccines include vomiting and diarrhoea. In a recent 208 
integrated analysis of the safety and reactogenicity of Rotarix® among >100,000 infants 209 
enrolled in 28 phase II and III clinical trials, the rates of any vomiting (17.8% vs. 17.0%) or 210 
diarrhoea (7.8% vs. 7.5%) as well as severe (Grade 3 intensity) vomiting (2.7% vs. 2.4%) or 211 
diarrhoea (4.9% vs. 4.5%) was similar among recipients of Rotarix® and the placebo group 212 
(15). Of the serious adverse events within 30 days of Rotarix® immunisation, however, 213 
gastroenteritis (0.27% vs. 0.39%; relative risk 0.65; 95% CI, 0.52-0.82; P=0.0002) and severe 214 
diarrhoea (0.03% vs. 0.06%; relative risk 0.48; 95% CI, 0.24-0.94; P=0.03) were both 215 
significantly less common in vaccinated infants compared to the placebo group. 216 
In Japan, where two live attenuated oral rotavirus vaccines (Rotarix® and Rotateq®) have 217 
been used voluntarily since 2011, analysis of 1,824 stool samples from children at outpatient 218 
clinics with acute gastroenteritis identified the Rotarix®vaccine-derived-G1P[8] strain in six 219 
of 372 (1.6%) rotavirus-positive samples and no Rotateq® vaccine-derived strains (16). Wild-220 
type rotavirus strains and other pathogens such as norovirus, Escherichia coli and enterovirus 221 
were also detected in two and four of the six samples, respectively, that were positive for the 222 
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Rotarix®vaccine-derived-G1P[8]  strain (16). The authors concluded that the contribution of 223 
the vaccine-derived strains to the children’s symptoms was unclear, although all six had been 224 
vaccinated 2-14 days before sample collection. In another study, diarrhoea post-vaccination 225 
was reported in 21% (13/61) of infants admitted to hospital within two weeks of receiving the 226 
Rotateq® vaccine (17). 227 
 228 
Given that both vomiting and diarrhoea (especially severe symptoms warranting medical 229 
attention) are uncommon adverse events following oral rotavirus vaccination, even when 230 
solicited in clinical trials, a key question that remains as to whether the vaccine-derived 231 
strains identified in the stool samples of symptomatic infants in this study was responsible for 232 
the illness or whether another pathology was involved. Additional assessments to identify the 233 
cause of the gastrointestinal symptoms, including identification of other pathogens in the 234 
stool sample, may help elucidate the role of the Rotarix®vaccine-derived-G1P[8] strains in 235 
such infants. In the meantime, clinicians should be cautious when assessing infants presenting 236 
with symptoms of acute gastroenteritis during the period after their rotavirus immunisations 237 
(typically, 2-5 months of age).  In particular, a rotavirus-positive stool sample in a recently 238 
immunised infant should be interpreted with caution unless, for G1[P8] strains, the presence 239 
of a Rotarix®vaccine-derived G1[P8] has been discounted, particularly in infants who are 240 
severely unwell, as there may be another cause of the illness. Another important 241 
consideration regarding oral rotavirus vaccination which has previously been reported is that 242 
clinicians should be aware of the small but significant increased risk of intussusception 243 
during the first week – and up to three weeks – after rotavirus immunisation, especially after 244 
the first dose of Rotarix® (18).  245 
 246 
Prolonged shedding and SCID 247 
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Infants with the Rotarix®vaccine-derived-G1P[8]  strains identified more than 7 weeks after 248 
they were given rotavirus immunisation period often had underlying SCID. Prolonged 249 
shedding of the Rotarix®vaccine-derived-G1P[8]  strain is well-reported in infants with SCID 250 
(19) and vaccination of SCID patients with live rotavirus vaccines, including Rotarix®, is 251 
contra-indicated. Infants with SCID can be diagnosed early through national newborn 252 
screening programmes but this is not universally implemented (20-22), including in England, 253 
although a pilot study is being planned. In countries without such a screening programme, 254 
infants with prolonged gastrointestinal symptoms after rotavirus vaccination and/or shedding 255 
of Rotarix®vaccine-derived strain, particularly more than seven weeks following the most 256 
recent immunisation, should be assessed for underlying immune deficiency, especially SCID 257 
(20).  258 
 259 
Transmission of vaccine-derived strains in the community 260 
Another important finding in our study was the lack of Rotarix®vaccine-derived-G1P[8]  261 
strains in the stools of unimmunised, symptomatic children during the first three years of the 262 
national  immunisation programme. Recent studies in neonatal intensive care units also did 263 
not identify any transmission of Rotarix®vaccine-derived-G1P[8]  strains from immunised to 264 
unimmunised infants (23-25). Transmission of the vaccine strain to unimmunised children 265 
has been reported, albeit infrequently, and is not associated with any symptoms in the 266 
recipients, which is reassuring (26-28). Evidence of such horizontal transmission events is 267 
important because it could help explain the indirect (population) protection afforded by the 268 
infant programme to unvaccinated children and adults in England (4) and elsewhere (29). 269 
 270 
Strengths and Limitations 271 
13 
The strength of this study lies in the enhanced national surveillance conducted by PHE that 272 
began prior to introduction of the rotavirus vaccine into the national immunisation 273 
programme (4). In addition to demonstrating population impact, we were able to monitor 274 
changes in circulating rotavirus strains following vaccine introduction (7). One limitation, 275 
however, was that sample submission rates from vaccine-eligible infants to PHE was 276 
relatively poor at the beginning of the programme but increased rapidly once the hospital 277 
laboratories implemented local protocols to prospectively submit positive samples to PHE. 278 
Additionally, stool samples were taken at the clinicians’ discretion and only from infants 279 
whose parents were sufficiently concerned about their child to seek medical attentions. It is 280 
also possible that clinicians may be more likely to submit stool samples from immunised 281 
infants because they would expect such infants to be protected against rotavirus 282 
gastroenteritis. Finally, the information needed to calculate the modified Vesikari score, was 283 
poorly completed because the individual parameters of the Vesikari score are not routinely 284 
recorded in the clinical records and the surveillance questionnaire was sent to GPs several 285 
weeks after the diagnosis was confirmed in the infant. 286 
 287 
Conclusions and Clinical Implications 288 
Clinicians should be aware that infants may develop acute gastroenteritis symptoms, 289 
especially diarrhoea, and have positive rotavirus stool tests after rotavirus vaccination. SCID 290 
remains the major contraindication to rotavirus vaccination; those with prolonged 291 
gastrointestinal symptoms and/or rotavirus-positive stools after vaccination should be 292 
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What is already known 310 
1. Rotavirus is the most common cause of acute gastroenteritis leading to hospitalisation 311 
in young children worldwide  312 
2.  The live attenuated oral rotavirus vaccines are highly effective in preventing severe 313 
rotavirus gastroenteritis and hospitalisations due to rotavirus gastroenteritis 314 
3. Hospital laboratories generally do not distinguish between wild-type rotavirus strains 315 
and vaccine strains in stool samples of symptomatic infants 316 
 317 
What this study adds 318 
 319 
1. After implementation of the rotavirus immunisation programme, 8% of rotavirus-320 
positive stool samples in vaccine-eligible infants were vaccine strains  321 
15 
2. Most vaccine strains were found in infants within 7 weeks of their first or second 322 
Rotarix® immunisation at 8 and 12 weeks of age.  323 
3. Infants with vaccine strains presented mainly with diarrhoea and were less likely to 324 
have fever, vomiting, dehydration or severe gastroenteritis than infants with wild 325 
type rotavirus. 326 
4. The majority of infants with vaccine strains in their stools more than 7 weeks after 327 








1. Giaquinto C, van Damme P. Age distribution of paediatric rotavirus gastroenteritis cases in 335 
Europe: the REVEAL study. Scand J Infect Dis. 2010;42(2):142-7. 336 
2. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal study of 337 
infectious intestinal disease in the UK (ID2 study): incidence in the community and presenting to 338 
general practice. Gut. 2012;61:69-77. 339 
3. Harris JP, Jit M, Cooper D, Edmunds WJ. Evaluating rotavirus vaccination in England and 340 
Wales. Part I. Estimating the burden of disease. Vaccine. 2007;25(20):3962-70. 341 
4. Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, et al. Rapid Declines in Age 342 
Group-Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated 343 
Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales. J Infect Dis. 344 
2016;213(2):243-9. 345 
5. Thomas SL, Walker JL, Fenty J, Atkins KE, Elliot AJ, Hughes HE, et al. Impact of the national 346 
rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted. 347 
Vaccine. 2017;35(4):680-6. 348 
6. Atchison CJ, Lopman BA, Harris CJ, Tam CC, Iturriza Gómara M, Gray J, J. Clinical laboratory 349 
practices for the detection of rotavirus in England and Wales: can surveillance based on routine 350 
laboratory testing data be used to evaluate the impact of vaccination? 351 
. Euro Surveillance. 2009;21:19127. 352 
7. Hungerford D, Allen DJ, Nawaz S, Collins S, Ladhani S, Vivancos R, et al. Impact of rotavirus 353 
vaccination on rotavirus genotype distribution and diversity in England, September 2006 to August 354 
2016. Euro Surveill. in press. 355 
8. Schnadower D, Tarr PI, Gorelick MH, O'Connell K, Roskind CG, Powell EC, et al. Validation of 356 
the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. Journal 357 
of pediatric gastroenterology and nutrition. 2013;57(4):514-9. 358 
9. Freedman SB, Eltorky M, Gorelick M. Evaluation of a gastroenteritis severity score for use in 359 
outpatient settings. Pediatrics. 2010;125(6):e1278-85. 360 
10. Iturriza Gomara M, Wong C, Blome S, Desselberger U, Gray J. Molecular characterization of 361 
VP6 genes of human rotavirus isolates: correlation of genogroups with subgroups and evidence of 362 
independent segregation. Journal of virology. 2002;76(13):6596-601. 363 
11. Iturriza Gomara M, Simpson R, Perault AM, Redpath C, Lorgelly P, Joshi D, et al. Structured 364 
surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral 365 
gastroenteric pathogens. Epidemiol Infect. 2008;136(1):23-33. 366 
12. Iturriza-Gomara M, Dallman T, Banyai K, Bottiger B, Buesa J, Diedrich S, et al. Rotavirus 367 
genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-368 
European collaborative strain surveillance network. Epidemiol Infect. 2011;139(6):895-909. 369 
13. Gautam R, Esona MD, Mijatovic-Rustempasic S, Ian Tam K, Gentsch JR, Bowen MD. Real-time 370 
RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix((R)) and RotaTeq((R)) 371 
vaccine strains in stool samples. Human vaccines & immunotherapeutics. 2014;10(3):767-77. 372 
14. EuroRotaNet network m. http://www.eurorota.net/docs.php [ 373 
15. Buyse H, Vinals C, Karkada N, Han HH. The human rotavirus vaccine Rotarix in infants: an 374 
integrated analysis of safety and reactogenicity. Human vaccines & immunotherapeutics. 375 
2014;10(1):19-24. 376 
16. Kaneko M, Takanashi S, Thongprachum A, Hanaoka N, Fujimoto T, Nagasawa K, et al. 377 
Identification of vaccine-derived rotavirus strains in children with acute gastroenteritis in Japan, 378 
2012-2015. PLoS One. 2017;12(9):e0184067. 379 
17 
17. Donato CM, Ch'ng LS, Boniface KF, Crawford NW, Buttery JP, Lyon M, et al. Identification of 380 
strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J 381 
Infect Dis. 2012;206(3):377-83. 382 
18. Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception following monovalent 383 
rotavirus vaccination in England: A self-controlled case-series evaluation Ref. No: JVAC-D-16-01124. 384 
Vaccine. 2016;34(50):6115. 385 
19. Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency 386 
(SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). 387 
Vaccine. 2010;28(40):6609-12. 388 
20. King JR, Hammarstrom L. Newborn Screening for Primary Immunodeficiency Diseases: 389 
History, Current and Future Practice. Journal of clinical immunology. 2018;38(1):56-66. 390 
21. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn 391 
screening for severe combined immunodeficiency in 11 screening programs in the United States. 392 
Jama. 2014;312(7):729-38. 393 
22. Chien YH, Yu HH, Lee NC, Ho HC, Kao SM, Lu MY, et al. Newborn screening for severe 394 
combined immunodeficiency in Taiwan. Int J Neonatal Screen 2017;3:16. 395 
23. Hiramatsu H, Suzuki R, Nagatani A, Boda H, Miyata M, Hattori F, et al. Rotavirus Vaccination 396 
Can Be Performed Without Viral Dissemination in the Neonatal Intensive Care Unit. J Infect Dis. 397 
2018;217(4):589-96. 398 
24. Hofstetter AM, Lacombe K, Klein EJ, Jones C, Strelitz B, Jacobson E, et al. Risk of Rotavirus 399 
Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Pediatrics. 2018;141(1). 400 
25. Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics. 401 
2014;133(6):e1555-60. 402 
26. Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH, Jr., et al. Comparative 403 
evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus 404 
vaccine. Pediatr Infect Dis J. 2005;24(6):481-8. 405 
27. Miura H, Kawamura Y, Sugata K, Koshiyama N, Yoshikawa A, Komoto S, et al. Rotavirus 406 
vaccine strain transmission by vaccinated infants in the foster home. Journal of medical virology. 407 
2017;89(1):79-84. 408 
28. Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, et al. Evaluation of RIX4414, a 409 
live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial 410 
involving 2464 Singaporean infants. J Infect Dis. 2005;192 Suppl 1:S6-s16. 411 
29. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. The Lancet 412 
Infectious diseases. 2008;8(10):642-9. 413 
 414 
  415 
18 
Table 1: Characteristics of cases by rotavirus strain type, England 2013-2015. 416 
 417 





Age, weeks 54.4 (43.3) 10.9 (4.6) P<0.001 
Age, months 12.5 (10.0) 2.5 (1.1) P<0.001 
    
Vomiting  305/411 (74.2%) 41/128 (32.0%) P <0.001 
Diarrhoea  401/424 (94.6%) 112/135 (83.0%) P <0.001 
Fever 180/372 (48.4%) 25/124 (20.2%) P <0.001 
Dehydration 97/387 (25.1%) 14/123 (11.4%) P =0.001 
Severity * 
  Mild/moderate (1-10) 









median (IQR), or n/N (%) 418 
*modified Vesikari Score (based on the information provided by the GP in the clinical 419 
questionnaire, a modified Vesikari score could be calculated for 128 infants with wild-type 420 
rotavirus infection and 41 infants with a Rotarix®vaccine-derived-G1P[8]  strain).  421 
 422 
 423 
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Figure 1 425 
Percentage of 207 Rotarix®vaccine-derived-G1P[8] strains and the time since most recent 426 
documented vaccination in weeks.  Underlying conditions of individuals with time since 427 
vaccination exceeding seven weeks are indicated.  428 
 429 
